A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors

NCT05028556 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic or Locally Advanced Solid Tumors

Interventions

DRUG: Cohort 1 of Y101D
DRUG: Cohort 2 of Y101D
DRUG: Cohort 3 of Y101D
DRUG: Cohort 4 of Y101D
DRUG: Cohort 5 of Y101D

Sponsor

Wuhan YZY Biopharma Co., Ltd.